Bellicum Pharmaceuticals, Inc. (BLCM)

Oncology Corporate Profile

Stock Performance

10.4300
-0.1000

HQ Location

6400 Fannin Street, Suite 2300
Houston, TX 77030

Company Description

Bellicum Pharmaceuticals, Inc. is developing clinical applications of chemical induction of dimerization (CID), a drug-based remote control technology that extends the physician's reach beyond the point at which a treatment has been administered. Bellicum's mission is to leverage this smart technology to bring safe, effective, innovative cell therapies to market for patients with serious and life threatening diseases. The company's DeCIDe™ vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific T cell immune response. Lead product BPX-101, an autologous DeCIDe™ vaccine, is in clinical development for patients with metastatic castrate resistant prostate cancer (mCRPC). CaspaCIDe™ is a cell therapy safety switch, permitting the rapid elimination of cells in the event of toxicity. CaspaCIDe™ DLI is a donor lymphocyte infusion administered following a hematopoietic stem cell transplant, in which the safety switch may be activated to resolve graft-versus-host disease (GVHD).

Website: http://www.bellicum.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BPX-501adjunct T-cell therapyAcute Myelogenous Leukemia (AML)I
BPX-501adjunct T-cell therapyPediatric Acute Lymphocytic Leukemia (ALL)I
BPX-501adjunct T-cell therapyVarious cancer typesI
BPX-701T-cell receptorAcute Myelogenous Leukemia (AML)Preclinical
CD19CAR-T cell therapyLeukemiaPreclinical
CD19CAR-T cell therapyLymphomaPreclinical
BPX-701T-cell receptorMyelodysplastic Syndrome (MDS)Preclinical
CD19CAR-T cell therapyPediatric Acute Lymphocytic Leukemia (ALL)Preclinical
BPX-601inducible MyD88/CD40 activiation moleculeProstate cancerPreclinical
BPX-701T-cell receptorVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.bellicum.com/

Recent News Headlines

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/18/2017 12:17 am

5/18/2017 12:17 am

5/18/2017 12:17 am

5/18/2017 12:17 am

5/18/2017 12:17 am

5/17/2017 12:17 pm

5/17/2017 12:17 pm

5/17/2017 12:17 pm

5/17/2017 12:17 pm

5/17/2017 12:17 pm

5/16/2017 06:17 am

5/16/2017 06:17 am

5/16/2017 06:17 am

5/16/2017 06:17 am

5/11/2017 12:17 pm

5/9/2017 06:17 am

5/8/2017 12:17 pm

4/26/2017 12:17 am

4/11/2017 06:17 am

Bellicum Pharmaceuticals Announces Closing of Public Offering

3/30/2017 11:00 am

[GlobeNewswire] - HOUSTON, March 30, 2017-- Bellicum Pharmaceuticals, Inc. today announced the closing, on March 29, 2017, of its previously announced underwritten public offering of 5,750,000 shares of its common stock, ...